NKTR Investor Alert: Nektar Therapeutics Securities Fraud Lawsuit - Investors With Losses May Seek to Lead the Class Action After Allegedly Misleading Institutional Shareholders: Levi & Ko...
Nektar Therapeutics (NKTR)
Last nektar therapeutics earnings: 2/27 04:15 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.nektar.com/investor-relations
Company Research
Source: GlobeNewswire
NEW YORK, April 20, 2026 (GLOBE NEWSWIRE) -- Institutional investors holding positions in Nektar Therapeutics (NASDAQ: NKTR) during the period from February 26, 2025 through December 15, 2025 may wish to evaluate lead plaintiff opportunities in a pending securities class action. Request an institutional investor loss assessment. You may also contact Joseph E. Levi, Esq. at jlevi@levikorsinsky.com or call (212) 363-7500. Shareholders who acquired NKTR securities during the Class Period suffered losses of $4.14 per share, a 7.77% decline, following corrective disclosures on December 16, 2025 revealing that Nektar's pivotal REZOLVE-AA clinical trial included ineligible patients whose participation allegedly compromised the study's statistical significance. Fiduciary Obligations and Recovery Options Pension funds, mutual funds, and asset managers with fiduciary duties to plan participants and beneficiaries should assess whether losses in NKTR positions trigger obligations to investig
Show less
Read more
Impact Snapshot
Event Time:
NKTR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NKTR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NKTR alerts
High impacting Nektar Therapeutics news events
Weekly update
A roundup of the hottest topics
NKTR
News
- Nektar Therapeutics: 'Strong Buy' On REZPEG POC Established In AD/AA And Late-Stage Development [Seeking Alpha]Seeking Alpha
- Nektar Therapeutics Announces Proposed Public Offering [TheStreet.com]TheStreet.com
- Nektar Therapeutics Announces Proposed Public OfferingPR Newswire
- Nektar Therapeutics (NKTR) Discusses 52-Week Topline Results From REZOLVE-AA Phase 2b Extension in Severe Alopecia Areata Transcript [Seeking Alpha]Seeking Alpha
- Nektar Therapeutics (NKTR) had its price target raised by HC Wainwright from $165.00 to $185.00. They now have a "buy" rating on the stock.MarketBeat
NKTR
Earnings
- 3/12/26 - Beat
NKTR
Sec Filings
- 4/20/26 - Form 424B5
- 4/20/26 - Form 8-K
- 4/20/26 - Form 8-K
- NKTR's page on the SEC website